Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy
Kentaro Mizuhara(Okayama University Hospital), Yoshinobu Maeda(Okayama University Hospital), Ken‐ichi Matsuoka(Okayama University), Noboru Asada(Okayama University), Keisuke Seike(University of Michigan), Yasuhisa Sando(Okayama University Hospital), Masaya Abe(Okayama University Hospital), Daisuke Ennishi(BC Cancer Agency), Hisakazu Nishimori(Okayama University Hospital), Takahide Takahashi(Okayama University Hospital), Yuki Fujiwara(University of Colorado Denver), Tomohiro Urata(Okayama University Hospital), Yuichi Sumii(Okayama University Hospital), Makoto Nakamura(Okayama University Hospital), Keiko Fujii(Okayama University Hospital), Kyosuke Saeki(Ehime Prefectural Central Hospital), Nobuharu Fujii(Okayama University Hospital), Michinori Aoe, Yusuke Meguri(Okayama University Hospital)
Cited by 6
Related Papers
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma
|Nature Communications|2018|148